Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Compass Therapeutics (NASDAQ: CMPX) to Report Phase 2/3 CTX-009 Data in Biliary Tract Cancer at ESMO

Compass Therapeutics (NASDAQ: CMPX) is scheduled to present Phase 2/3 results from a randomized controlled trial of CTX-009, a DLL4 x VEGF-A bispecific antibody, in biliary tract cancer at the ESMO 2026 congress on October 24.

Nitish Kishor | 20 July 2026

Immatics (NASDAQ: IMTX) to Provide IMA402 Clinical Update in Solid Tumors at ESMO 2026

Immatics N.V. (NASDAQ: IMTX) is scheduled to provide a Phase 1/2 clinical data update on IMA402 in solid tumors at the ESMO 2026 congress on October 24.

Nitish Kishor | 20 July 2026

Trevi Therapeutics (NASDAQ: TRVI) Shares Gain 10% Ahead of Industry Conference Appearances

Trevi Therapeutics (NASDAQ: TRVI) shares closed up 10% at $19.07 after the company announced its leadership team will participate in a series of upcoming industry events centered on its lead candidate, Haduvio.

Nitish Kishor | 20 July 2026

STAAR Surgical (NASDAQ: STAA) Shares Fall 9% Despite Preliminary Q2 Revenue Above $90 Million

STAAR Surgical (NASDAQ: STAA) shares closed down 9% at $26.44 even as the company projected preliminary second-quarter 2026 revenue surpassing $90 million, more than double the $44.3 million reported in the same period a year earlier.

Nitish Kishor | 20 July 2026

Meta Title:Jasper Therapeutics (NASDAQ: JSPR) Merges With Kira

Jasper Therapeutics (NASDAQ: JSPR) shares closed up 14% at $0.89 after the company completed an all-stock acquisition of Kira Pharmaceuticals in conjunction with a $132 million private placement.

Nitish Kishor | 20 July 2026

Cosmos Health (NASDAQ: COSM) Shares Fall 16% Despite Continued Share Buyback Activity

Cosmos Health (NASDAQ: COSM) shares closed down 16% at $0.23 even as the company continued repurchasing stock under its existing buyback program, acquiring an additional 274,000 shares at a mean price of $0.2554.

Nitish Kishor | 20 July 2026

Xencor (NASDAQ: XNCR) Shares Rise 17% After XmAb819 Selected for Oral Presentation at ESMO 2026

Xencor Inc. (NASDAQ: XNCR) shares closed up 17% at $17.47 after the company announced that Phase 1 expansion-cohort data for XmAb819 in advanced clear cell renal cell carcinoma has been selected for a proffered oral presentation at the ESMO 2026 congress, scheduled for October …

Nitish Kishor | 20 July 2026

Intuitive Surgical (NASDAQ: ISRG) Shares Fall 14% Despite 19% Revenue Growth in Second Quarter

Intuitive Surgical (NASDAQ: ISRG) shares closed down 14% at $345.42 after the company reported second-quarter revenue of $2.89 billion, up 19% from a year earlier, driven by higher procedure volumes and continued rollout of its newest surgical platform.

Nitish Kishor | 20 July 2026

REGENXBIO (NASDAQ: RGNX) Shares Fall 12% After Company Prices $100 Million Public Offering

REGENXBIO Inc. (NASDAQ: RGNX) shares closed down 12% at $9.89 after the gene-therapy company finalized the pricing of a $100 million public offering, a financing move that dilutes existing shareholders even as it adds capital to the balance sheet.

Nitish Kishor | 20 July 2026

US Markets Rebound in Futures as Middle East Risks, Inflation and AI Spending Concerns Drive Volatility

US equities ended lower on Friday as a renewed chip-sector sell-off and escalating geopolitical risks weighed on sentiment. The S&P 500 fell 1%, the Nasdaq declined 1.5% and the Dow lost 407 points, with Nvidia, Broadcom, AMD and Intel retreating on concerns that AI …

Team Kalkine | 20 July 2026
Support

Hi! How can we help you today?

Loading…